Rodman & Renshaw initiated coverage of Monopar Therapeutics with a Buy rating and $50 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics initiates Phase 1a trial for MNPR-101-Lu
- Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial
- Monopar Therapeutics Reports Positive MNPR-101-Zr Trial Results
- Monopar Therapeutics announces early human clinical data for MNPR-101-Zr
- Monopar Therapeutics regains compliance with Nasdaq minimum bid price rule